[DU2] Contribution of Prolonged-Release Melatonin and Anti-Benzodiazepine Campaigns to the Reduction of Benzodiazepine and Z-Drug Consumption in Nine European Countries

[DU2] Contribution of Prolonged-Release Melatonin and Anti-Benzodiazepine Campaigns to the Reduction of Benzodiazepine and Z-Drug Consumption in Nine European Countries

2012 Value in health

Clay, E. | Falissard, B. | Moore, N. | Toumi, M. | Volume: 15, Issue: 7, Pages: A286, Podium session, Melatonin,

Insomnia is mostly treated by benzodiazepine (BZD) or Z-drugs that are efficacious but are also associated with safety issues like dependence and rebound insomnia. These safety concerns may present a major public health issue, particularly for the elderly. Prolonged-release (PR) melatonin is a non-sedative hypnotic that has demonstrated clinically relevant efficacy on quality of sleep and morning alertness, with a good safety profile. Several clinical trials demonstrated that the PR-melatonin could help reduce BZD/Z-drugs consumption.